All Posts By

Smartkarma Daily Briefs

Daily Brief Thematic (Sector/Industry): GEMWeekly (9 Aug 2024): HBM Chip Stockpiling; China Macro; Samsung and more

By | Daily Briefs, Thematic (Sector/Industry)

In today’s briefing:

  • GEMWeekly (9 Aug 2024): HBM Chip Stockpiling; China Macro; Samsung, Infosys, SK Hynix


GEMWeekly (9 Aug 2024): HBM Chip Stockpiling; China Macro; Samsung, Infosys, SK Hynix

By Wium Malan, CFA


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief ECM: ECM Weekly (12th Aug 2024) – Ola Electric and more

By | Daily Briefs, ECM

In today’s briefing:

  • ECM Weekly (12th Aug 2024) – Ola Electric, Brainbees, WeRide, Akum, CR Beverages, Eternal Beauty


ECM Weekly (12th Aug 2024) – Ola Electric, Brainbees, WeRide, Akum, CR Beverages, Eternal Beauty

By Sumeet Singh

  • Aequitas Research’s weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.
  • On the IPO front, the prior week witnessed a number of listings with divergent results.
  • Given the market volatility, there was only one large placements in the prior week.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Event-Driven: Merger Arb Mondays (12 Aug) – China TCM and more

By | Daily Briefs, Event-Driven

In today’s briefing:

  • Merger Arb Mondays (12 Aug) – China TCM, Canvest, GA Pack, Fuji Soft, Fancl, Descente, Takiron
  • Flow Developments to Watch as the Release of the Value-Up Index Approaches
  • Swire Properties (1972 HK): Buyback to Offset Passive Selling
  • Lineage (LINE): Year’s Biggest IPO Failed Fast-Entry. Addition Coming Soon.
  • Taiwan Top 50 ETF Rebalance Preview: One Change Right at the Cusp



Flow Developments to Watch as the Release of the Value-Up Index Approaches

By Sanghyun Park

  • The plan is to select 20 large-cap companies from around 30 with value-up disclosures by late August, then gradually expand the index’s constituents.
  • Investors seeking both dividends and value-up benefits must buy stocks individually, as ETFs lack tax advantages, potentially triggering fund shifts from dividend ETFs to value-up stocks.
  • We can target stocks in dividend ETFs not making value-up disclosures, as they may face overhang risk during fund migration to the value-up index.

Swire Properties (1972 HK): Buyback to Offset Passive Selling

By Brian Freitas

  • Swire Properties (1972 HK) was trending lower on expectations of deletion from a global index in August. Short interest has jumped a lot over the last few months.
  • The announcement of the buyback last week took the stock higher. The increased real float from the index deletion will be offset by the buyback.
  • Swire Pacific (A) (19 HK)‘s ownership of Swire Properties (1972 HK) will increase from 82% to 83.5% following the buyback and cancellation of the shares. Privatisation at some point?

Lineage (LINE): Year’s Biggest IPO Failed Fast-Entry. Addition Coming Soon.

By Dimitris Ioannidis

  • Lineage (LINE US) , with an IPO market cap of ~$18bn failed the fast-entry threshold of both main global indices with the threshold being more than ~$28bn. 
  • Based on the listing date of 25 July 2024, its addition is forecasted for September 2024, December 2024 and February 2025 in US and Global indices.
  • Lineage (LINE US) is expected to get added to the Top 1000 US companies index with forecasted demand of ~$340m and ~1.3 ADV at close of 20 September 2024.

Taiwan Top 50 ETF Rebalance Preview: One Change Right at the Cusp

By Brian Freitas


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Equity Bottom-Up: Taiwan Dual-Listings Monitor: TSMC Strong Spread Rebound Into Short Zone; ASE Remains Broken Down and more

By | Daily Briefs, Equity Bottom-Up

In today’s briefing:

  • Taiwan Dual-Listings Monitor: TSMC Strong Spread Rebound Into Short Zone; ASE Remains Broken Down
  • China Healthcare Weekly (Aug.11) – 2024 NRDL Negotiation, China Biotech Outlook, Bottom Fish CanSino
  • Taiwan Tech Weekly: Watch Hon Hai & Zhen Ding Guidance for Servers, AI PCs/Mobiles, and IPhone 16
  • Shortlist Of High Conviction Ideas: Income, Value, and Margin of Safety – August 2024
  • BeiGene (6160.HK/BGNE.US) 24Q2 – It Is Time to Open a New Chapter in China’s Pharmaceutical Industry
  • Pacific Basin (2343 HK): Looking for a 2H24 Upturn
  • Maersk Q224 Results | Strangely, Danish Container Giant Saw Limited Gains From Higher Spot Rates
  • Zylox-Tonbridge Medical Technology (2190.HK) – A Good Alpha-Generating Opportunity for Investors
  • Pointerra Ltd – New contracts from existing customer builds FY25 base
  • Ollamani (AGUILCPO MM) – Thursday, May 9, 2024


Taiwan Dual-Listings Monitor: TSMC Strong Spread Rebound Into Short Zone; ASE Remains Broken Down

By Vincent Fernando, CFA

  • TSMC: +16.1% Premium; Strong Spread Rebound, Potential Opportunity to Short the Spread
  • UMC: +1.6% Premium; Consider Shorting the Spread at This Level
  • ASE: +3.8% Premium; Uncertainty Remains on the Sustainability of the Recent Breakdown

China Healthcare Weekly (Aug.11) – 2024 NRDL Negotiation, China Biotech Outlook, Bottom Fish CanSino

By Xinyao (Criss) Wang

  • We summarized the varieties that would miss 2024 NRDL negotiation and have to wait until 2026 to enter medical insurance coverage. This however means competing products would have more advantages.
  • As the NRDL negotiation becomes more transparent/reasonable, there will be a balance point among companies’ profits, patient affordability and medical insurance budget. So, there’s no need to be overly pessimistic.
  • The approval process of CanSino’s PCV13i could be faster than expected. 2024 is the best time to bottom-fish this stock. Reasonable market value is at least RMB5 billion.

Taiwan Tech Weekly: Watch Hon Hai & Zhen Ding Guidance for Servers, AI PCs/Mobiles, and IPhone 16

By Vincent Fernando, CFA

  • Last Week — TSMC’s July Revenue Soared, Asustek Guided for PC Growth Acceleration, While KYEC, Mediatek, and UMC Rebounded
  • Key Events — This Week Look to Hon Hai & Zhen Ding Earnings and Guidance for Servers, AI PCs/Mobiles, iPhone 16
  • PC Monitor: Promising Uptake of Microsoft Copilot and AI Services; Remain Structurally Long 

Shortlist Of High Conviction Ideas: Income, Value, and Margin of Safety – August 2024

By Sameer Taneja


BeiGene (6160.HK/BGNE.US) 24Q2 – It Is Time to Open a New Chapter in China’s Pharmaceutical Industry

By Xinyao (Criss) Wang

  • BeiGene’s 24Q2 results far exceeded expectations. Sales of BRUKINSA may exceed that of Calquence for the first time next year. Breakeven in 2024 becomes possible if effective cost control continues.
  • BeiGene’s 2024 revenue could exceed Hengrui, marking the official transition of China’s innovative pharmaceutical industry from the old generation to the new one. Reasonable market value for BeiGene is US$19-27.5bn.
  • Current valuation cannot reflect strong fundamentals.As BeiGene has established a convincing profit model, the market turmoil actually provides investors with a good opportunity to buy the stock at low price.

Pacific Basin (2343 HK): Looking for a 2H24 Upturn

By Osbert Tang, CFA

  • Pacific Basin Shipping (2343 HK) may realise at least US$60m of revenue, or around 10% higher total TCE, in 2H24, based on its solid forward vessel coverage.  
  • Sustained re-routing of vessels due to Middle East tension and higher demand from China due to fixed asset spending are supportive of rates. FFA is now 3-4% higher than spot.
  • The stock is inexpensive at 9.7x PER and 0.8x P/B, and its 7.6% dividend yield is attractive. A solid balance sheet also means an upside on the payout ratio. 

Maersk Q224 Results | Strangely, Danish Container Giant Saw Limited Gains From Higher Spot Rates

By Daniel Hellberg

  • Despite rising spot rates, Maersk Q224 revenue and EBITDA both fell Y/Y
  • After lifting pessimistic guidance in June, Maersk upped FY24 targets again
  • We believe Maersk probably moved to limit spot exposure a year ago

Zylox-Tonbridge Medical Technology (2190.HK) – A Good Alpha-Generating Opportunity for Investors

By Xinyao (Criss) Wang

  • Zylox is a beneficiary of VBP and it has turned losses into profits. 2024 full-year revenue could be up 40-50% YoY. Net profit could be close to RMB100 million.
  • Whether in terms of the number of products on the market or the efficiency of R&D, Zylox’s performance is superior to peers.Its valuation is expected to be higher than peers.
  • We’re in a bear market, together with weak liquidity, Zylox’s valuation doesn’t fully reflect its strong fundamentals. So, while this is a good company, investors may need to be patient.

Pointerra Ltd – New contracts from existing customer builds FY25 base

By Research as a Service (RaaS)

  • RaaS has published a flash comment on 3D spatial data solutions group Pointerra (ASX:3DP) after its announcement that it has been awarded US$0.8m in new contracts by existing US energy utility customer Florida Power & Light (FPL).
  • The contracts will see Pointerra3D, the company’s AI-driven analytics platform, used to extract information and insights from 3D LiDAR and 2D imagery data.
  • We view the contracts as a positive sign that the contract delays and deferrals experienced by Pointerra in FY24 in its dealings with the US energy utility sector are coming to an end.

Ollamani (AGUILCPO MM) – Thursday, May 9, 2024

By Value Investors Club

  • AGUIL is a sports/casino operator spun out of Televisa, with potential for earnings growth through expansion of casinos and broadcast rights for Club America soccer team
  • Current market cap of $320 million and low valuation of 9x current PE make AGUIL an attractive investment opportunity
  • Recent purchases of stock by Emilio Azcarraga Jean from Televisa US ADR holders further support long-term upside potential for AGUIL

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Macro: Data Dependent Fed Unfazed by Fallout from Unwinding Carry Trades and more

By | Daily Briefs, Macro

In today’s briefing:

  • Data Dependent Fed Unfazed by Fallout from Unwinding Carry Trades
  • Assessing the Damage: It’s Not Just the Carry Trade
  • What Will Lead the Anticipated Market Rebound?
  • Central Bank of Turkey Keeps Its End-Year Inflation Forecast Unchanged at 38%
  • China: CPI Still Weak for July and Forecast of Upcoming Government Measures
  • Reserve Bank of India Faces Critical Decision


Data Dependent Fed Unfazed by Fallout from Unwinding Carry Trades

By Said Desaque

  • Financial markets took fright from the weaker than expected July Employment Situation report. Fed policy remains data-dependent and the Fed will wait for more data to formulate an appropriate response.
  • BoJ policy has seemingly broken the attraction of the yen carry trade, beneficial for US equities in 2024. Financial market volatility has forced the BoJ to postpone policy rate increases. 
  • The case for an emergency Fed policy rate cut remains unconvincing, particularly when current circumstances are compared to other instances of inter-meeting policy rate reductions back in 2020 and 2001.

Assessing the Damage: It’s Not Just the Carry Trade

By Cam Hui

  • The recent disorderly risk-off episode can be attributed to the unwind of a series of trades that depend on a low-volatility and complacent environment.
  • Historically, such unwinds have resolved in volatility spikes and higher equity returns soon afterwards
  • The current environment is supportive of a quick market recovery, though the risk of a LTCM-style blowup could see a longer and more complex market bottom.

What Will Lead the Anticipated Market Rebound?

By Cam Hui

  • Numerous historical studies of volatility spikes indicate that the stock market is poised for renewed strength.
  • A review of market leadership shows weakness by technology and other large-cap growth stocks.
  • We believe the rotation from growth to value and from large caps to small caps will continue and these stocks will be the new leadership in the next leg up.

Central Bank of Turkey Keeps Its End-Year Inflation Forecast Unchanged at 38%

By Alex Ng

  • Central Bank of Turkiye (CBRT) released its third quarterly inflation report of the year on August 8, and did not change its inflation forecasts and policy guidance.
  • CBRT projects that inflation will fall to 38% at end-2024, and kept its forecasts for 2025 and 2026 unchanged at 14% and 9%, respectively, emphasizing the disinflation process has started.
  • We envisage CPI to cool off to 50%’s in August on base effects coupled with tightened monetary and fiscal policies, additional macro prudential measures, and relative

China: CPI Still Weak for July and Forecast of Upcoming Government Measures

By Alex Ng

  • July CPI up 0.5% y/y vs June +0.2%, PPI -0.8% y/y vs June -0.8%.
  • CPI uptick comes as Beijing boosts support for weak consumer sector, but core CPI still weaker than previous month.
  • Overall data outcome such as weak CPI, strain on exports, and soft domestic demand backs expectations for more stimulus.

Reserve Bank of India Faces Critical Decision

By Alex Ng

  • The calls for a rate cut are rising in the Indian market, but this is unlikely to impact the RBI’s upcoming decision.
  • The RBI will retain its stance of withdrawal of accomodation and maintain benchmark rate of 6.5% in its August meeting, staying on the path of inflation target.
  • Concerns around high borrowing costs are rising, which could change the RBI’s stance.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Australia: Pointerra Ltd and more

By | Australia, Daily Briefs

In today’s briefing:

  • Pointerra Ltd – New contracts from existing customer builds FY25 base


Pointerra Ltd – New contracts from existing customer builds FY25 base

By Research as a Service (RaaS)

  • RaaS has published a flash comment on 3D spatial data solutions group Pointerra (ASX:3DP) after its announcement that it has been awarded US$0.8m in new contracts by existing US energy utility customer Florida Power & Light (FPL).
  • The contracts will see Pointerra3D, the company’s AI-driven analytics platform, used to extract information and insights from 3D LiDAR and 2D imagery data.
  • We view the contracts as a positive sign that the contract delays and deferrals experienced by Pointerra in FY24 in its dealings with the US energy utility sector are coming to an end.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief South Korea: Hyundai Motor and more

By | Daily Briefs, South Korea

In today’s briefing:

  • Flow Developments to Watch as the Release of the Value-Up Index Approaches


Flow Developments to Watch as the Release of the Value-Up Index Approaches

By Sanghyun Park

  • The plan is to select 20 large-cap companies from around 30 with value-up disclosures by late August, then gradually expand the index’s constituents.
  • Investors seeking both dividends and value-up benefits must buy stocks individually, as ETFs lack tax advantages, potentially triggering fund shifts from dividend ETFs to value-up stocks.
  • We can target stocks in dividend ETFs not making value-up disclosures, as they may face overhang risk during fund migration to the value-up index.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief United States: Lineage and more

By | Daily Briefs, United States

In today’s briefing:

  • Lineage (LINE): Year’s Biggest IPO Failed Fast-Entry. Addition Coming Soon.


Lineage (LINE): Year’s Biggest IPO Failed Fast-Entry. Addition Coming Soon.

By Dimitris Ioannidis

  • Lineage (LINE US) , with an IPO market cap of ~$18bn failed the fast-entry threshold of both main global indices with the threshold being more than ~$28bn. 
  • Based on the listing date of 25 July 2024, its addition is forecasted for September 2024, December 2024 and February 2025 in US and Global indices.
  • Lineage (LINE US) is expected to get added to the Top 1000 US companies index with forecasted demand of ~$340m and ~1.3 ADV at close of 20 September 2024.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief China: China Traditional Chinese Medicine, Swire Properties, CanSino Biologics , Plover Bay Technologies, BeiGene , Pacific Basin Shipping, China Resources Beverage, Zylox-Tonbridge Medical Technology, Shui On Land and more

By | China, Daily Briefs

In today’s briefing:

  • Merger Arb Mondays (12 Aug) – China TCM, Canvest, GA Pack, Fuji Soft, Fancl, Descente, Takiron
  • Swire Properties (1972 HK): Buyback to Offset Passive Selling
  • China Healthcare Weekly (Aug.11) – 2024 NRDL Negotiation, China Biotech Outlook, Bottom Fish CanSino
  • Shortlist Of High Conviction Ideas: Income, Value, and Margin of Safety – August 2024
  • BeiGene (6160.HK/BGNE.US) 24Q2 – It Is Time to Open a New Chapter in China’s Pharmaceutical Industry
  • Pacific Basin (2343 HK): Looking for a 2H24 Upturn
  • ECM Weekly (12th Aug 2024) – Ola Electric, Brainbees, WeRide, Akum, CR Beverages, Eternal Beauty
  • Zylox-Tonbridge Medical Technology (2190.HK) – A Good Alpha-Generating Opportunity for Investors
  • Morning Views Asia: Adani Green Energy, New World Development, Rakuten, Shui On Land
  • Morning Views Asia: Adani Green Energy, New World Development, Rakuten, Shui On Land



Swire Properties (1972 HK): Buyback to Offset Passive Selling

By Brian Freitas

  • Swire Properties (1972 HK) was trending lower on expectations of deletion from a global index in August. Short interest has jumped a lot over the last few months.
  • The announcement of the buyback last week took the stock higher. The increased real float from the index deletion will be offset by the buyback.
  • Swire Pacific (A) (19 HK)‘s ownership of Swire Properties (1972 HK) will increase from 82% to 83.5% following the buyback and cancellation of the shares. Privatisation at some point?

China Healthcare Weekly (Aug.11) – 2024 NRDL Negotiation, China Biotech Outlook, Bottom Fish CanSino

By Xinyao (Criss) Wang

  • We summarized the varieties that would miss 2024 NRDL negotiation and have to wait until 2026 to enter medical insurance coverage. This however means competing products would have more advantages.
  • As the NRDL negotiation becomes more transparent/reasonable, there will be a balance point among companies’ profits, patient affordability and medical insurance budget. So, there’s no need to be overly pessimistic.
  • The approval process of CanSino’s PCV13i could be faster than expected. 2024 is the best time to bottom-fish this stock. Reasonable market value is at least RMB5 billion.

Shortlist Of High Conviction Ideas: Income, Value, and Margin of Safety – August 2024

By Sameer Taneja


BeiGene (6160.HK/BGNE.US) 24Q2 – It Is Time to Open a New Chapter in China’s Pharmaceutical Industry

By Xinyao (Criss) Wang

  • BeiGene’s 24Q2 results far exceeded expectations. Sales of BRUKINSA may exceed that of Calquence for the first time next year. Breakeven in 2024 becomes possible if effective cost control continues.
  • BeiGene’s 2024 revenue could exceed Hengrui, marking the official transition of China’s innovative pharmaceutical industry from the old generation to the new one. Reasonable market value for BeiGene is US$19-27.5bn.
  • Current valuation cannot reflect strong fundamentals.As BeiGene has established a convincing profit model, the market turmoil actually provides investors with a good opportunity to buy the stock at low price.

Pacific Basin (2343 HK): Looking for a 2H24 Upturn

By Osbert Tang, CFA

  • Pacific Basin Shipping (2343 HK) may realise at least US$60m of revenue, or around 10% higher total TCE, in 2H24, based on its solid forward vessel coverage.  
  • Sustained re-routing of vessels due to Middle East tension and higher demand from China due to fixed asset spending are supportive of rates. FFA is now 3-4% higher than spot.
  • The stock is inexpensive at 9.7x PER and 0.8x P/B, and its 7.6% dividend yield is attractive. A solid balance sheet also means an upside on the payout ratio. 

ECM Weekly (12th Aug 2024) – Ola Electric, Brainbees, WeRide, Akum, CR Beverages, Eternal Beauty

By Sumeet Singh

  • Aequitas Research’s weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.
  • On the IPO front, the prior week witnessed a number of listings with divergent results.
  • Given the market volatility, there was only one large placements in the prior week.

Zylox-Tonbridge Medical Technology (2190.HK) – A Good Alpha-Generating Opportunity for Investors

By Xinyao (Criss) Wang

  • Zylox is a beneficiary of VBP and it has turned losses into profits. 2024 full-year revenue could be up 40-50% YoY. Net profit could be close to RMB100 million.
  • Whether in terms of the number of products on the market or the efficiency of R&D, Zylox’s performance is superior to peers.Its valuation is expected to be higher than peers.
  • We’re in a bear market, together with weak liquidity, Zylox’s valuation doesn’t fully reflect its strong fundamentals. So, while this is a good company, investors may need to be patient.

Morning Views Asia: Adani Green Energy, New World Development, Rakuten, Shui On Land

By Leonard Law, CFA

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


Morning Views Asia: Adani Green Energy, New World Development, Rakuten, Shui On Land

By Leonard Law, CFA

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Japan: TSE Tokyo Price Index TOPIX and more

By | Daily Briefs, Japan

In today’s briefing:

  • To Be Selected by Global Investors as an Investment Target, Increasing Cash Flow Is Crucial


To Be Selected by Global Investors as an Investment Target, Increasing Cash Flow Is Crucial

By Aki Matsumoto

  • The positive impact of increased dividends must be discounted because seniors, who receive most dividends, are non-working generations and are more vulnerable to the negative impact of rising consumer prices.
  • The high level of cash on hand should be used effectively for investments and shareholder returns. Looking at listed companies as a whole, both ROE and DOE are below FY2018.
  • Although the too-low dividend payout of Japanese companies have been corrected, the fact that ROE is still low means that few companies are chosen as investment targets by global investors.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars